EMA (EU)
GUIDANCE FINAL
Draft guideline on the clinical requirements for medicines intended for the treatment of sickle cell disease
Published: 9/24/2026Detected: 9/24/2026
Summary preview
Sets out EMA CHMP/HAEMWP clinical development expectations for medicines targeting sickle cell disease, including how to design confirmatory efficacy studies, select patients, and define efficacy and safety endpoints.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accounthematology
pediatrics
clinical
safety
labeling
manufacturing
#sickle cell disease
#vaso-occlusive crises
#haemolysis
#clinical requirements
#confirmatory studies
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026